...
首页> 外文期刊>Acta biomaterialia >Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics.
【24h】

Poly-L-lysine-coated albumin nanoparticles: stability, mechanism for increasing in vitro enzymatic resilience, and siRNA release characteristics.

机译:聚-L-赖氨酸包被的白蛋白纳米颗粒:稳定性,增加体外酶弹性的机制和siRNA释放特性。

获取原文
获取原文并翻译 | 示例

摘要

Enzymatic degradation of nanoparticle (NP)-based drug delivery vehicles is a major factor influencing the administration routes as well as the site-specific delivery of NPs. To understand the stability of albumin NPs in an aggressive proteolytic environment, bovine serum albumin (BSA) NPs were fabricated via a coacervation technique and stabilized by coating using different molecular weights (MWs: 0.9-24 kDa) and concentrations (0.1-1.0 mg ml(-1)) of the cationic polymer, poly-L-lysine (PLL). A short interfering ribonucleic acid (siRNA) was used as a model drug for encapsulation in the BSA NPs. The generated NPs were characterized for morphology (with atomic force microscopy), size (with photon correlation spectroscopy) and charge (zeta-potential). The size range of formed BSA particles (155 +/- 11 to 3800 +/- 1600 nm) was effectively controlled by the MW and concentration of the PLL used for coating. The aqueous solution stability of NPs increased with an increasing MW and PLL concentration. However, in the presence of trypsin, NPs coated with higher MW PLL were not as stable as those formed using lower MW PLL. This trend was also confirmed based on the release pattern of siRNA in the presence of trypsin. We conclude that, when designing stabilizing coatings for soft protein-based NPs, smaller molecules may be more suitable for particle coating if enhanced proteolytic resistance and more stable NPs are desired for targeted drug delivery applications.
机译:基于纳米颗粒(NP)的药物递送载体的酶促降解是影响NP给药途径和部位特异性递送的主要因素。为了了解白蛋白NP在侵蚀性蛋白水解环境中的稳定性,通过凝聚技术制备了牛血清白蛋白(BSA)NP,并使用不同的分子量(MWs:0.9-24 kDa)和浓度(0.1-1.0 mg ml (-1))的阳离子聚合物,聚L-赖氨酸(PLL)。短干扰核糖核酸(siRNA)用作模型药物,用于包封在BSA NP中。生成的NPs的形态(原子力显微镜),大小(光子相关光谱)和电荷(ζ电位)进行了表征。形成的BSA颗粒的尺寸范围(155 +/- 11至3800 +/- 1600 nm)可通过MW和用于涂层的PLL的浓度有效控制。 NP的水溶液稳定性随MW和PLL浓度的增加而增加。但是,在存在胰蛋白酶的情况下,涂有较高MW PLL的NP不如使用较低MW PLL形成的NP稳定。基于存在胰蛋白酶的siRNA的释放模式也证实了这种趋势。我们得出的结论是,在设计基于软蛋白的NP的稳定涂层时,如果需要增强的蛋白水解抗性和更稳定的NP用于靶向药物输送应用,则较小的分子可能更适合于颗粒涂层。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号